Biomerica, Inc. announced advancements in the roll out of the inFoods IBS product. Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company's new salesforce has activated over 30 new Gastrointestinal (GI) physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company's revolutionary inFoods® IBS Product to their IBS patients.

Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community. The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions.

This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for irritable bowel syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters. Biomerica Advances Intellectual Property Portfolio: Biomerica has also been issued notices of allowance on five new patents in Japan, Canada and the EU, for a total of 25 pending/issued patents worldwide. These allowed/issued patents cover the Company?s inFoods Technology and validate the novelty of this technology.

The American College of Gastroenterology (ACG) reports that IBS impacts 1 in 20 Americans and that up to $10 Billion is spent each year in direct medical cost due to IBS. Yet, due to the complexity of the disorder, and the lack of effective therapies, IBS patients still struggle to find effective relief. The inFoods IBS product has been studied in a prospective double blinded, placebo-controlled endpoint study at several prominent medical centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. ?

a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The study results demonstrated a significant improvement in Abdominal Pain Intensity (API) (trial participants with >30% reduction in pain) for IBS patients in the treatment diet arm compared to those in the placebo diet arm (p-value of 0.0246). Biomerica remains at the forefront of innovative GI solutions, with the inFoods IBS product exemplifying its dedication to improving patient lives.

The Company remains steadfast in its mission to enhance gastrointestinal care, reduce healthcare costs, and improve the quality of life of approximately 750 million individuals suffering from IBS around the world.